D. Kass, S. Strock, M. Nouraie, J. Chiarchiaro, K. Veraldi, Yingze Zhang, K. Gibson
{"title":"Differential Expression of Plasma Metabolites in Patients with Pulmonary Sarcoidosis is Associated with Clinical Behavior","authors":"D. Kass, S. Strock, M. Nouraie, J. Chiarchiaro, K. Veraldi, Yingze Zhang, K. Gibson","doi":"10.1183/13993003.CONGRESS-2018.PA5215","DOIUrl":null,"url":null,"abstract":"Introduction: We hypothesized that a comprehensive metabolomic analysis of plasma from sarcoid patients (pts) would identify potential biomarkers of disease severity. Methods & Results: This study is a cross-sectional analysis of sarcoid pts seen at our Center between February 2003 and July 2014. Plasma from 60 pulmonary sarcoid patients and 40 aged-matched donor controls were tested (Table 1) was subjected to metabolomic profiling (Metabolon) for 893 known biochemicals. Following normalization to volume extracted, log transformation and imputation of missing values, if any, with the minimum observed value for each compound, ANOVA contrasts and Welch’s two-sample t-test were used to identify biochemicals that differed significantly between experimental groups. Differential expression of chemicals that were decreased in sarcoid included steroids, but notably not prednisone, which is consistent with steroid treatment and adrenal suppression. Differential expression of chemicals that were increased in sarcoid mapped to amino acid metabolism. In sarcoid pts only, based on Pearson correlations, one amino acid, N-acetylthreonine, was associated with FVC (R=−0.38, P Conclusion: Metabolomics profiling for biomarker discovery in sarcoid is feasible, and candidate biomarkers should be prioritized for further testing.","PeriodicalId":439129,"journal":{"name":"Sarcoidosis and other granulomatous ILD/DPLD","volume":"82 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoidosis and other granulomatous ILD/DPLD","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/13993003.CONGRESS-2018.PA5215","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Introduction: We hypothesized that a comprehensive metabolomic analysis of plasma from sarcoid patients (pts) would identify potential biomarkers of disease severity. Methods & Results: This study is a cross-sectional analysis of sarcoid pts seen at our Center between February 2003 and July 2014. Plasma from 60 pulmonary sarcoid patients and 40 aged-matched donor controls were tested (Table 1) was subjected to metabolomic profiling (Metabolon) for 893 known biochemicals. Following normalization to volume extracted, log transformation and imputation of missing values, if any, with the minimum observed value for each compound, ANOVA contrasts and Welch’s two-sample t-test were used to identify biochemicals that differed significantly between experimental groups. Differential expression of chemicals that were decreased in sarcoid included steroids, but notably not prednisone, which is consistent with steroid treatment and adrenal suppression. Differential expression of chemicals that were increased in sarcoid mapped to amino acid metabolism. In sarcoid pts only, based on Pearson correlations, one amino acid, N-acetylthreonine, was associated with FVC (R=−0.38, P Conclusion: Metabolomics profiling for biomarker discovery in sarcoid is feasible, and candidate biomarkers should be prioritized for further testing.